Toxicity as prime selection criterion among SARS-active herbal medications.

摘要: We present here a new selection criterion for prioritizing research on efficacious drugs the fight against COVID-19: relative toxicity versus safety of herbal medications, which were effective SARS in 2002/2003 epidemic. rank these medicines according to their as basis preferential rapid potential treatment COVID-19. The data demonstrate that from toxicological information nothing speaks immediate investigation on, followed by implementation Lonicera japonica, Morus alba, Forsythia suspensa, and Codonopsis spec. COVID-19 patients. Glycyrrhiza Panax ginseng are ranked second priority ephedrine-free Herba Ephedrae extract third (followed several lower preferences). Rapid efficacy therapy - well under specific circumstances equally will provide substantial advantages Public Health including availability, enlargement medicinal possibilities, cases where other means not successful (non-responders), tolerated (sensitive individuals) or just available (as is presently case) thus minimize sufferings save lives. Moreover, moderate costs convenient oral application especially advantageous underprivileged populations developing countries.